BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Munsie M, Lysaght T, Hendl T, Tan HL, Kerridge I, Stewart C. Open for business: a comparative study of websites selling autologous stem cells in Australia and Japan. Regen Med. 2017;12:777-790. [PMID: 29125016 DOI: 10.2217/rme-2017-0070] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Matthews KRW. Unproven Stem Cell-Based Interventions: Addressing Patients’ Unmet Needs or Causing Patient Harms? Philosophy and Medicine 2023. [DOI: 10.1007/978-3-031-12692-5_6] [Reference Citation Analysis]
2 Smith C, Crowley A, Munsie M, Behfar A, DeMartino ES, Staff NP, Shapiro SA, Master Z. Academic Physician Specialists' Approaches to Counseling Patients Interested in Unproven Stem Cell and Regenerative Therapies-A Qualitative Analysis. Mayo Clin Proc 2021;96:3086-96. [PMID: 34454715 DOI: 10.1016/j.mayocp.2021.06.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Cook M, Richey A, Brafman DA, Frow EK. Weighing up the evidence used by direct-to-consumer stem cell businesses. Stem Cell Reports 2021:S2213-6711(21)00542-7. [PMID: 34767748 DOI: 10.1016/j.stemcr.2021.10.007] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Rudge C, Ghinea N, Munsie M, Stewart C. Regulating autologous stem cell interventions in Australia: updated review of the direct-to-consumer advertising restrictions. Aust Health Rev 2021;45:507-15. [PMID: 33952390 DOI: 10.1071/AH20217] [Reference Citation Analysis]
5 Al-Sowayan BS, Al-Shareeda AT. Stem cells and the pursuit of youth, a tale of limitless possibilities and commercial fraud. World J Biol Chem 2021; 12(4): 52-56 [PMID: 34354805 DOI: 10.4331/wjbc.v12.i4.52] [Reference Citation Analysis]
6 Master Z, Matthews KRW, Abou-El-Enein M. Unproven stem cell interventions: A global public health problem requiring global deliberation. Stem Cell Reports 2021;16:1435-45. [PMID: 34107243 DOI: 10.1016/j.stemcr.2021.05.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
7 Chavez J, Shah NA, Ruoss S, Cuomo RE, Ward SR, Mackey TK. Online marketing practices of regenerative medicine clinics in US-Mexico border region: a web surveillance study. Stem Cell Res Ther 2021;12:189. [PMID: 33736697 DOI: 10.1186/s13287-021-02254-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Ikonomou L, Wagner DE, Turner L, Weiss DJ. Translating Basic Research into Safe and Effective Cell-based Treatments for Respiratory Diseases. Ann Am Thorac Soc 2019;16:657-68. [PMID: 30917290 DOI: 10.1513/AnnalsATS.201812-890CME] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
9 Smith C, Martin-Lillie C, Higano JD, Turner L, Phu S, Arthurs J, Nelson TJ, Shapiro S, Master Z. Challenging misinformation and engaging patients: characterizing a regenerative medicine consult service. Regen Med 2020;15:1427-40. [PMID: 32319855 DOI: 10.2217/rme-2020-0018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
10 Ghinea N, Munsie M, Rudge C, Stewart C. Australian regulation of autologous human cell and tissue products: implications for commercial stem cell clinics. Regenerative Medicine 2020;15:1361-9. [DOI: 10.2217/rme-2019-0124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Waldby C, Hendl T, Kerridge I, Lipworth W, Lysaght T, Munsie M, Stewart C. The direct-to-consumer market for stem cell-based interventions in Australia: exploring the experiences of patients. Regenerative Medicine 2020;15:1238-49. [DOI: 10.2217/rme-2019-0089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Zarzeczny A, Tanner C, Barfoot J, Blackburn C, Couturier A, Munsie M. Contact us for more information: an analysis of public enquiries about stem cells. Regenerative Medicine 2019;14:1137-50. [DOI: 10.2217/rme-2019-0092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
13 Zarzeczny A. The Future of Stem Cell Research and its Clinical Translation in Canada: Exploring Questions of Governance and Policy Options. Adv Exp Med Biol 2020;1247:1-16. [PMID: 31749135 DOI: 10.1007/5584_2019_450] [Reference Citation Analysis]
14 Sugarman J, Barker RA, Kerridge I, Lysaght T, Pellegrini G, Sipp D, Tanner C. Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report. Stem Cell Reports 2018;11:1021-5. [PMID: 30428384 DOI: 10.1016/j.stemcr.2018.10.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
15 Hamon M, Hauser PV. Cell Therapy: Past, Present, and Future. Curr Transpl Rep 2019;6:109-118. [DOI: 10.1007/s40472-019-00235-4] [Reference Citation Analysis]
16 Macgregor C, Petersen A, Munsie M. From the margins to mainstream: How providers of autologous ‘stem cell treatments’ legitimise their practice in Australia. Health (London) 2021;25:51-68. [DOI: 10.1177/1363459319846927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Turner L. Direct-to-consumer marketing of stem cell interventions by Canadian businesses. Regenerative Medicine 2018;13:643-58. [DOI: 10.2217/rme-2018-0033] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
18 Lysaght T, Munsie M, Castricum A, Hui JH, Okada K, Sato Y, Sawa Y, Stewart C, Tan LK, Tan LH, Sugii S. A roundtable on responsible innovation with autologous stem cells in Australia, Japan and Singapore. Cytotherapy 2018;20:1103-9. [DOI: 10.1016/j.jcyt.2018.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Bobba S, Di Girolamo N, Munsie M, Chen F, Pébay A, Harkin D, Hewitt AW, O'Connor M, McLenachan S, Shadforth AMA, Watson SL. The current state of stem cell therapy for ocular disease. Exp Eye Res 2018;177:65-75. [PMID: 30029023 DOI: 10.1016/j.exer.2018.07.019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
20 Snyder J, Turner L. Selling stem cell ‘treatments’ as research: prospective customer perspectives from crowdfunding campaigns. Regenerative Medicine 2018;13:375-84. [DOI: 10.2217/rme-2018-0007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
21 Horner C, Tenenbaum E, Sipp D, Master Z. Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions. NPJ Regen Med 2018;3:5. [PMID: 29479481 DOI: 10.1038/s41536-018-0043-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
22 Barfoot J, Rosemann A, Blackburn CC. Special focus issue on regenerative medicine in society: interdisciplinary perspectives (part II) - Foreword. Regen Med 2017;12:733-6. [PMID: 29111912 DOI: 10.2217/rme-2017-0136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]